<unk> , sold under the brand name Fotivda, is a medication used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). It is an oral VEGF receptor tyrosine kinase inhibitor. The most common side effects include fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis.<unk>  was approved for medical use in the European Union in August 2017, and in the United States in March 2021.
Tivozanib
Vatalanib
Pegaptanib
Pazopanib
Nintedanib
Abrocitinib
Gilteritinib
Erdafitinib